Heat-stable ritonavir tablets: A new formulation of a pharmacokinetic enhancer for HIV

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 1, 2011, Pages 141-148

  Sherman, Elizabeth M ^a   Steinberg, Jennifer G ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral; HIV; Norvir; Protease inhibitor; Ritonavir; Tablet

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ABDOMINAL PAIN; ALLERGIC REACTION; ANOREXIA; ARTICLE; ASTHENIA; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; DYSPEPSIA; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTRANSAMINASEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALAISE; NAUSEA; PANCREATITIS; PARESTHESIA; PHARMACIST; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TABLET FORMULATION; TASTE DISORDER; VOMITING;

CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HOT TEMPERATURE; HUMANS; RITONAVIR; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 78650492362     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.542151     Document Type: Article

References (24)

1. Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update 2009. Available from: http://data.unaids.org/pub/Report/ 2009/ JC1700-Epi-Update-2009-en.pdf. [Accessed 12th October 2010]
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1st December 2009. p. 1-161. Available from: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. [Accessed 12 October 2010]
3. European AIDS Clinical Society. Clinical management and treatment of HIV infected adults in Europe (version 5-2). Available from: http://www. europeanaidsclinicalsociety.org/ guidelinespdf/EACS-EuroGuidelines- FullVersion.pdf. [Accessed 12 October 2010]
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. Available from: http://whqlibdoc.who.int/publications/ 2010/9789241599764-eng.pdf [Accessed 12 October 2010]
5. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9
6. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-13
7. Abbott Laboratories. Abbott received U.S. FDA approval for heat-stable Norvir- (ritonavir) tablets. 11th February 2010. Available from: http://www.abbott.com/ global/url/pressRelease/en-US/60.5:5/ Press-Release-0820.htm [Accessed 12 October 2010]
8. Tho I, Liepold B, Rosenberg J, et al. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. Eur J Pharm Sci 2010;40:25-32
9. Ng J, Klein C, Causemaker C, et al. A comparison of the single dose bioavailability of a ritonavir tablet formulation relative to the ritonavir soft gelatin capsule in healthy adult subjects [abstract TUPE0076]. 17th International AIDS Conference; 3 - 8 August 2008; Mexico City, Mexico. Poster available from: www.medadvocates.org/resources/ conferences/international-aids- conferences/17/lopinavir-index/17N.pdf
10. Klein C, Chiu YL, Awni W, et al. A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects [abstract THAB04]. 17th International AIDS Conference; 3 - 8 August 2008; Mexico City, Mexico
11. Klein CE, Chiu YL, Awni W, et al. The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects [abstractP247]. 7th International Congress on Drug Therapy in HIV Infection; 9 - 13 November 2008 Glasgow, Scotland, Poster available from: www. hivandhepatitis.com/2008icr/hiv9/docs/ posters/ KleinRTVtablet.pdf
12. Abbott Laboratories, Norvir-, ritonavir tablets, oral solution prescribing information. North Chicago, IL; 2010
13. Abbott Laboratories, Norvir-, ritonavir capsules (soft gelatin) prescribing information. North Chicago, IL; 2010
14. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007;44:401-10
15. Gathe J, da Silva B, Loutfy M, et al. Study M05-730 Primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir DF + emtricitabine in ARV-naive HIV-1 infected subjects [abstract 775]. 15th Conference on Retroviruses and Opportunistic Infections (CROI). 3 - 6 February 2008. Boston, MA
16. Schrader S, Chuck SK, Rahn LW, et al. Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. AIDS Res Ther 2008;5:21
17. Ofotokun I, Chuck SK, Schmotzer B, ONeil KL. Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients. AIDS Res Ther 2009;6:29
18. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-69
19. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304
20. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
21. Elion R, Gathe J, Rashbaum B, et al. The single-tablet regimen elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/ TDF; QUAD) maintains a high rate of virologic suppression, and cobicistat is an effective pharmacoenhancer through 48 weeks [poster H-938B]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 - 15 September 2010; Boston, MA
22. German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55(3):323-9
23. Mathias A, Liu HC, Warren D, et al. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir [abstract 28]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7 - 9 April 2010; Sorrento, Italy
24. Ramanatham S, Warren D, Wei L, Kearney BP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir [poster A1-1301]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 - 15 September, 2009 San Francisco, CA